Company Focus
Alnylam Pharmaceuticals
Latest Alnylam Pharmaceuticals News
Pharmaceutical
The chronic hepatitis D market is expected to grow steadily through 2034, supported by a small but advancing pipeline targeting a long-standing unmet need, according to research from DelveInsight. 30 January 2026
Related News
Insights
Company Spotlight
A clinical-stage biopharma company developing selective fatty acid synthase (FASN) inhibitors for diseases driven by dysregulated lipid metabolism and fibrosis, with current priorities in MASH and acne.
Latest News & Features of interest to Alnylam Pharmaceuticals
Pharmaceutical
US drug developer Cytokinetics today announced that Myqorzo (aficamten) is now available for prescription in 5mg, 10mg, 15mg and 20mg tablets in the USA. 27 January 2026
Pharmaceutical
Swiss pharma giant Roche has announced positive top-line results from CT388-103, a Phase II trial of CT-388, an investigational dual GLP-1/GIP receptor agonist being developed for the treatment of obesity. 27 January 2026
Biotechnology
Chinese biotech Huahui Health has won conditional approval for Libevitug (libevitug) to treat adults with chronic hepatitis D virus infection, with or without compensated cirrhosis. The decision makes Libevitug the first approved therapy for hepatitis D in China and addresses a long-standing clinical void. 27 January 2026
Pharmaceutical
Postmenopausal women receiving menopausal hormone therapy lost 35% more weight while taking tirzepatide, an obesity drug sold by Eli Lilly under the brand name Mounjaro. 26 January 2026
Biotechnology
Japan’s Eisai and US biotech Biogen have announced that the US Food and Drug Administration (FDA) has accepted for review the former’s Supplemental Biologics License Application (sBLA) for lecanemab-irmb subcutaneous autoinjector (SC-AI), branded as Leqembi Iqlik, as a weekly starting dose. 26 January 2026
Generics
Sun Pharmaceutical Industries has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection. 23 January 2026
Biotechnology
US clinical-stage biotech Corxel Pharmaceuticals, dedicated to developing innovative therapies for patients with cardiometabolic conditions around the world, today announced the successful completion of its Series D1 financing, raising up to $287 million in capital. 22 January 2026
Pharmaceutical
Texas, USA-based IntraBio revealed that the European Commission granted marketing authorization to Aqneursa (levacetylleucine) for the treatment of neurological manifestations of Niemann-Pick Type C (NPC) disease, following a positive opinion from the European Medicines Agency (EMA) human medicines committee, CHMP. 22 January 2026
Pharmaceutical
The Gates Foundation, Novo Nordisk Foundation, and Wellcome have said they will award $60 million in new grant funding over the next three years to support early-stage research aimed at speeding antibiotic discovery, as antimicrobial resistance keeps eroding the usefulness of existing drugs. 22 January 2026
Pharmaceutical
DelveInsight says the cystinosis treatment market across the USA, EU4, UK and Japan totaled about $250 million in 2024, with the USA accounting for roughly 84% of sales. The research group also estimates 1,540 diagnosed prevalent cases across those markets in 2024, underscoring how concentrated care remains in specialist metabolic and nephrology centers. 22 January 2026
Latest In Brief for Alnylam Pharmaceuticals
Pharmaceutical
French pharma major Sanofi is preparing an offer to acquire the US biopharmaceutical firm Ocular Therapeutix, according to a report by French publication La Lettre. 16 January 2026
Latest Relevant Ones To Watch News
The 11.7% economic interest in specialist HIV company ViiV Healthcare that is currently held by US pharma giant Pfizer is to be replaced with an investment by Japanese drugmaker Shionogi, it has been announced. 20 January 2026
13 January 2026
8 January 2026
6 January 2026
22 December 2025
12 December 2025
Relevant Ones to Watch Companies
Refine search
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze